Signos Inc. raised $20 million [1] in a Series B funding round to expand its glucose-monitoring platform for weight management.
The move signals a growing market for consumer-facing metabolic health tools. By integrating medical-grade hardware with weight-loss software, the company aims to provide users with real-time data on how food and exercise affect their blood sugar levels.
Signos produces the first FDA-cleared over-the-counter continuous glucose monitoring (CGM) system designed specifically for weight management [1]. The company said the funding and an expanded partnership with Dexcom were announced Oct. 24, 2023 [2]. This collaboration allows the platform to become more widely available to consumers in the U.S. [1].
Under the terms of the partnership, the device will be sold through Dexcom’s Stelo website [1]. The company said it intends to use the new capital to accelerate the growth of its platform as the demand for weight-loss tools increases [1].
Continuous glucose monitors were traditionally reserved for people with diabetes. However, the shift toward over-the-counter access for weight management reflects a broader trend in the health-tech industry to move chronic disease tools into the wellness sector. This approach allows non-diabetic users to track glucose spikes and dips to optimize their diets for weight loss [1].
The funding round was announced by the U.S.-based company to scale its operations and reach a larger user base [1]. By leveraging Dexcom's existing infrastructure, Signos can distribute its hardware more efficiently while focusing on the software analytics that guide user behavior [1].
“Signos raised $20 million in a Series B funding round”
The expansion of Signos and its partnership with Dexcom reflects the commercialization of metabolic health. By moving CGM technology from a clinical necessity for diabetics to a consumer tool for weight loss, the industry is betting that real-time biological feedback will replace traditional calorie counting as the primary driver for weight management.
